Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Mohamed Okily"'
Autor:
Hermine I Brunner, Nicolino Ruperto, Clarissa A Pilkington, Damon L Bass, Mohamed Okily, Holly Quasny, Fengchun Zhang, Syuji Takei, Carlos Abud-Mendoza, Diego O Viola, Beulah N Ji, David A Roth, Masaaki Mori, Sandra Navarra, Reema Syed, Gina Eriksson, Anne E Hammer
Publikováno v:
RMD Open, Vol 7, Iss 3 (2021)
Externí odkaz:
https://doaj.org/article/c028e3050036431689b5ae65af0ceb84
Autor:
Richard Furie, Brad H. Rovin, Frédéric Houssiau, Gabriel Contreras, Y.K. Onno Teng, Paula Curtis, Yulia Green, Mohamed Okily, Anuradha Madan, David A. Roth
Publikováno v:
Clinical Journal of the American Society of Nephrology, 17(11), 1620-1630. AMER SOC NEPHROLOGY
Background and objectives In the BLISS-LN study, belimumab improved kidney outcomes in adult patients with active lupus nephritis. This 28-week open-label extension of BLISS-LN assessed belimumab's safety and efficacy. Design, setting, participants,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0dd426eb5d4c1905380c305c756ce802
https://doi.org/10.2215/cjn.02520322
https://doi.org/10.2215/cjn.02520322
Autor:
Xueqing Yu, Nan Chen, Jun Xue, Chi Chiu Mok, Sang-Cheol Bae, Xiaomei Peng, Wei Chen, Hong Ren, Xiao Li, Kajohnsak Noppakun, Jennifer A. Gilbride, Yulia Green, Beulah Ji, Chang Liu, Anuradha Madan, Mohamed Okily, Chun-Hang Tang, David A. Roth
Publikováno v:
American Journal of Kidney Diseases. 81:294-306.e1
Belimumab improved renal outcomes in patients with active lupus nephritis (LN) in BLISS-LN, leading to its approval in the USA and EU. As data on treatment of East Asian patients with LN are limited, we evaluated the efficacy and safety of belimumab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::493bdc583e4ce3e883d32e5b1aac387b
https://doi.org/10.1053/j.ajkd.2022.06.013
https://doi.org/10.1053/j.ajkd.2022.06.013